Is the US prepared to deal with another pandemic or widespread health crisis?

I will assess US pandemic preparedness using recent expert reports, official assessments, and key metrics.Gathering details from key reports on US biodefense, stockpiles, and assessments.No, the US is not fully prepared for another pandemic or widespread health crisis, though it is substantially better positioned in several key areas than it was before COVID-19. Assessments from government watchdogs, bipartisan commissions, official roadmaps, and indices paint a mixed picture: strong technical and material capabilities on paper, paired with persistent gaps in coordination, sustained funding, leadership, supply chain resilience, and implementation of lessons learned.[1]

Strengths and Improvements

The US ranks 1st out of 195 countries on the Global Health Security (GHS) Index (score of ~83.5/100 in recent assessments), far above the global average (~40). It scores especially high in detection/reporting (near 98), prevention, biosafety/biosecurity, laboratory systems, and certain response planning elements.[1]

Post-COVID investments have yielded concrete gains:

•Strategic National Stockpile (SNS): Dramatically expanded. It now holds far more PPE (e.g., reports of 70x N95 respirators, 34x gloves, 50x isolation gowns pre-pandemic levels in some accounts), ~10x more ventilators, and other countermeasures. It has supported responses to H5N1 (distributing millions of PPE pieces), mpox (vaccines/therapeutics), and other incidents. Jurisdictional (state/local) stockpiles are also being emphasized as a layered system.[2]

•Surveillance and data: Major expansions in wastewater monitoring, electronic case reporting (from under 200 facilities pre-pandemic to over 45,000–48,000), syndromic surveillance, and data platforms (e.g., CDC’s “One CDC” efforts).[3]

•Medical countermeasures and platforms: Advances via BARDA and others in vaccines (including mRNA adaptability for threats like H5N1, with stockpiles of relevant doses and development funding), diagnostics, therapeutics, and “warm base” manufacturing capacity. Rapid response tools and approvals have improved.

•Organizational changes: Creation of the White House Office of Pandemic Preparedness and Response Policy (OPPR) in 2023 for coordination. Investments in global health security (billions since 2020), domestic industrial base efforts for PPE/supply chains, and programs like Health Care Coalitions and Medical Reserve Corps.

•Recent responses: Demonstrated capacity against mpox, H5N1 bird flu (in dairy cattle and limited human cases), and other outbreaks, including testing, PPE deployment, and vaccine sharing/donations. Biden-era roadmaps and strategies outlined playbooks for future threats.[4]

These build on frameworks like the Pandemic and All-Hazards Preparedness Act (PAHPA) and Public Health Emergency Medical Countermeasures Enterprise (PHEMCE).

Persistent Gaps and Vulnerabilities

Expert and oversight bodies emphasize that capabilities do not fully translate to readiness, and many COVID lessons remain unaddressed:

•Leadership and coordination: The Bipartisan Commission on Biodefense’s 2024 National Blueprint for Biodefense states the nation “remains dangerously vulnerable” and calls for “immediate action.” It notes fragmented responsibilities across 15+ departments/agencies and urges stronger White House leadership (e.g., codifying National Security Advisor role, deputy for day-to-day biodefense), a quadrennial biodefense review, and better strategy implementation. GAO has kept HHS leadership/coordination of public health emergencies on its High-Risk List since 2022 due to “persistent deficiencies.” As of recent updates, many criteria are only partially met or unmet; hundreds of COVID-related GAO recommendations (out of 400+) remain open or unimplemented, covering testing strategies, data systems, workforce, after-action reviews, and interagency collaboration.[5]

•Funding and sustainability: Boom-bust cycles—surge funding during crises followed by cuts—hinder long-term infrastructure, workforce, and stockpiles. PHEMCE has projected multi-billion-dollar shortfalls. Public health infrastructure at state/local levels remains strained.

•Supply chains and manufacturing: Domestic PPE production capacity expanded temporarily but faced collapse as demand dropped; reliance on foreign sources and raw materials persists. Stockpiles help but are insufficient alone for a prolonged, nationwide surge (as COVID showed). Experts call for “warm base” manufacturing, better stockpiling strategies (e.g., more reusable respirators), and industrial policy.[6]

•Detection, One Health, and specific systems: BioWatch (airborne detection) is widely criticized as ineffective after two decades. Animal-human health coordination gaps are evident in the ongoing H5N1 dairy cattle outbreak (farmer reluctance to test, limited worker testing). Surveillance improvements are real but incomplete for novel or engineered threats.

•Other issues: Healthcare capacity/access inequities, risk communication and public trust challenges (exacerbated by polarization), workforce shortages/burnout, diagnostic testing strategy gaps, and biosafety/biosecurity oversight for high-risk research. Global cooperation faces hurdles (e.g., US rejection of certain 2024 WHO International Health Regulations amendments over sovereignty concerns).[7]

The Commission’s scenario of a hypothetical engineered pathogen attack illustrates how delays in recognition, fragmented response, and unaddressed vulnerabilities could lead to catastrophic outcomes. Stimson Center and others note that while some progress occurred, many structural issues (equity, trust, state-federal coordination) endure, and attention has waned.[5]

Overall Assessment

The US has stronger stockpiles, surveillance tools, countermeasure platforms, and institutional frameworks than in early 2020, ranking at the top globally on objective indices. It can likely handle smaller or contained outbreaks more effectively and has playbooks/roadmaps for larger ones. However, for a severe, fast-moving, novel, or multi-wave pandemic (or deliberate biological incident), significant risks remain due to coordination failures, funding instability, fragile domestic production, incomplete lesson implementation, and non-technical factors like trust and politics.

Preparedness is a continuum, not a binary. Experts across the spectrum (bipartisan commissions, GAO, think tanks) agree more sustained investment, leadership reforms, One Health integration, resilient manufacturing, and political will are needed now—before the next crisis—to close the gap between potential and actual readiness. Political transitions can accelerate or reverse gains, underscoring the need for durable, bipartisan approaches. Ongoing threats like H5N1 serve as real-time tests of these systems.

Citations (7)

1ghsindex.orgData and tools
https://ghsindex.org/country/united-states/
Backs: “strong technical and material capabilities on paper, paired with persistent gaps in coordination, sustained funding, leadership, supply chain resilience, and implementation of lessons learned.”
2archives.govGovernment
https://bidenwhitehouse.archives.gov/briefing-room/statements-releases/2025/01/14/report-the-biden-harris-administration-roadmap-for-pandemic-preparedness-and-response/
Backs: “It has supported responses to H5N1 (distributing millions of PPE pieces), mpox (vaccines/therapeutics), and other incidents. Jurisdictional (state/local) stockpiles are also being emphasized as a layered system.”
3cdc.govGovernment
https://www.cdc.gov/washington/testimony/2024/t20241114.htm
Backs: “Surveillance and data: Major expansions in wastewater monitoring, electronic case reporting (from under 200 facilities pre-pandemic to over 45,000–48,000), syndromic surveillance, and data platforms (e.g., CDC’s “One CDC” efforts).”
4apnews.comNews and mediaquality 1.00
https://apnews.com/article/pandemic-preparedness-trump-biden-192518a8e1414cf40bafefdc2bf1f5ca
Backs: “Recent responses: Demonstrated capacity against mpox, H5N1 bird flu (in dairy cattle and limited human cases), and other outbreaks, including testing, PPE deployment, and vaccine sharing/donations.”
5stimson.orgNonprofits and think tanks
https://www.stimson.org/2024/prepare-for-the-next-biothreat-now/
Backs: “GAO has kept HHS leadership/coordination of public health emergencies on its High-Risk List since 2022 due to “persistent deficiencies.” As of recent updates, many criteria are only partially met or unmet; hundreds of COVID-related GAO recommendations (out of 400+) remain open or unimplemented, covering testing…”
6thebulletin.orgNews and mediaquality 0.82
https://thebulletin.org/2024/07/how-the-us-gained-and-then-lost-the-ability-to-make-medical-masks/
Backs: “Stockpiles help but are insufficient alone for a prolonged, nationwide surge (as COVID showed). Experts call for “warm base” manufacturing, better stockpiling strategies (e.g., more reusable respirators), and industrial policy.”
7reuters.comNews and mediaquality 1.00
https://www.reuters.com/legal/litigation/us-rejects-who-pandemic-changes-global-health-rules-2025-07-18/
Backs: “Other issues: Healthcare capacity/access inequities, risk communication and public trust challenges (exacerbated by polarization), workforce shortages/burnout, diagnostic testing strategy gaps, and biosafety/biosecurity oversight for high-risk research. Global cooperation faces hurdles (e.g., US rejection of certain…”